Revision as of 04:20, 18 October 2016

Interactive Points | Codrops

iGEM 2016 NUS SINGAPORE

Parts Registry

RIOT Sensor

Part Number	Part Description	Characterised?	Link
BBa_K1897019	p70-34-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897019
BBa_K1897020	p70-32-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897020
BBa_K1897021	p70-33-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897021
BBa_K1897022	p62-34-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897022
BBa_K1897023	p62-32-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897023
BBa_K1897024	p62-33-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897024
BBa_K1897025	J23100-34-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897025
BBa_K1897026	J23100-32-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897026
BBa_K1897027	J23100-33-ALR-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897027
BBa_K1897028	p70-33-sfGFP-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897028
BBa_K1897029	p62-33-sfGFP-Terminator	Yes	http://parts.igem.org/Part:BBa_K1897029

RIOT RESPONDER

Part Number	Part Description	Characterised?	Link
BBa_K1897000	HasA coding sequence	Yes, in BBa_K1897001	http://parts.igem.org/Part:BBa_ K1897000
BBa_K1897001	HasA expression unit	Yes	http://parts.igem.org/Part:BBa_ K1897001
		Yes, in BBa_K1897007	http://parts.igem.org/Part:BBa_ K1897002
BBa_K1897003	HasS coding sequence	Yes, in BBa_K1897007	http://parts.igem.org/Part:BBa_ K1897003
BBa_K1897005	HasI coding sequence	Yes, in BBa_K1897007	http://parts.igem.org/Part:BBa_ K1897005
		Yes, in BBa_K1897007	http://parts.igem.org/Part:BBa_ K1897006
BBa_K1897007	Complete Has operon (controlling expression of LuxR)	Yes	http://parts.igem.org/Part:BBa_ K1897007

RIOT Invader

Part Number	Part Description	Characterised?	Link
BBa_K1897008	Constitutively expressed LuxR	Yes, in BBa_K1897016	http://parts.igem.org/Part:BBa_ K1897008
BBa_K1897009	pLuxR-controlled LuxI	Yes, by Western blot of BBa_K1897015	http://parts.igem.org/Part:BBa_ K1897009
			http://parts.igem.org/Part:BBa_ K1897011
BBa_K1897013	pLuxR-controlled Listeriolysin O	Yes, by Western blot via cotransformation with BBa_K1897008 in pSB4A5	http://parts.igem.org/Part:BBa_ K1897013
BBa_K1897014	pLuxR-controlled GFP	Yes, in BBa_K1897016	http://parts.igem.org/Part:BBa_ K1897014
BBa_K1897015	Constitutively expressed LuxR and pLuxR-controlled LuxI	Yes, by Western blot in pSB1K3	http://parts.igem.org/Part:BBa_ K1897015
BBa_K1897016	Constitutively expressed LuxR and pLuxR-controlled GFP	Yes	http://parts.igem.org/Part:BBa_ K1897016
			http://parts.igem.org/Part:BBa_ K1897017

Go To Top

@@ Line 171: / Line 171: @@
 								<p class="medium">RIOT Invader</p>
 							</header>
-							<p>In cancer treatment, specificity, sensitivity and reliability of diagnosis is the gold criteria of any diagnostic method. The RIOT System employs a novel method of cancer detection, relying on spatial markers that are intrinsic to the tumour microenvironment. Two types of spatial markers are used to increase specificity and ensure that only cancerous cells are targeted. The first spatial marker would be the elevated concentration of lactate usually found around tumours due to the Warburg effect. The second marker would be the detection of CD44v6, a cell surface marker that is upregulated on a variety of cancers. These spatial markers were specially chosen to circumvent a common problem in cancer research, where heterogeneity in different types of cancers results in the lack of a specific diagnostic for a variety of cancers. As elevated lactate concentration is ubiquitous among solid tumours and CD44v6 is present in different types of cancers, our RIOT System has the potential to be a diagnostic that can be applied to multiple cancers, which is advantageous in the current market where broad spectrum diagnostics for cancer are currently lacking. Furthermore, the utility of RIOT System can extend beyond just being a diagnostic and can be modified to deliver a drug payload, potentially acting as both a diagnostic and therapeutic. </p></br>
+							<p><table class="tableizer-table">
+<thead><tr class="tableizer-firstrow"><th>Part Number</th><th>Part Description</th><th>Characterised?</th><th>Link</th></tr></thead><tbody>
-<p>Based on our preliminary market analysis of the diagnostics industry, our proposed RIOT System stands out as one of the few in vivo options available for cancer detection. Current cancer diagnostics rely mainly on in vitro laboratory tests for detection of cancer biomarkers (e.g. blood, urine), imaging scans (e.g. CT scans, MRI) or physical examinations to detect the tumour. Thus, our RIOT System offers a radically different diagnostic option that sets itself apart from the current diagnostics. </p></br>
+ <tr><td>BBa_K1897008</td><td>Constitutively expressed LuxR</td><td>Yes, in BBa_K1897016</td><td><a href="http://parts.igem.org/Part:BBa_ K1897008">http://parts.igem.org/Part:BBa_ K1897008</a></td></tr>
+ <tr><td>BBa_K1897009</td><td>pLuxR-controlled LuxI</td><td>Yes, by Western blot of BBa_K1897015</td><td><a href="http://parts.igem.org/Part:BBa_ K1897009">http://parts.igem.org/Part:BBa_ K1897009</a></td></tr>
+ <tr><td></td><td></td><td></td><td><a href="http://parts.igem.org/Part:BBa_ K1897011">http://parts.igem.org/Part:BBa_ K1897011</a></td></tr>
+ <tr><td>BBa_K1897013</td><td>pLuxR-controlled Listeriolysin O</td><td>Yes, by Western blot via cotransformation with BBa_K1897008 in pSB4A5</a></td><td><a href="http://parts.igem.org/Part:BBa_ K1897013">http://parts.igem.org/Part:BBa_ K1897013</a></td></tr>
+ <tr><td>BBa_K1897014</td><td>pLuxR-controlled GFP</td><td>Yes, in BBa_K1897016</td><td><a href="http://parts.igem.org/Part:BBa_ K1897014">http://parts.igem.org/Part:BBa_ K1897014</a></td></tr>
+ <tr><td>BBa_K1897015</td><td>Constitutively expressed LuxR and pLuxR-controlled LuxI</td><td>Yes, by Western blot in pSB1K3</td><td><a href="http://parts.igem.org/Part:BBa_ K1897015">http://parts.igem.org/Part:BBa_ K1897015</a></td></tr>
+ <tr><td>BBa_K1897016</td><td>Constitutively expressed LuxR and pLuxR-controlled GFP</td><td>Yes</td><td><a href="http://parts.igem.org/Part:BBa_ K1897016">http://parts.igem.org/Part:BBa_ K1897016</a></td></tr>
+ <tr><td></td><td></td><td></td><td><a href="http://parts.igem.org/Part:BBa_ K1897017">http://parts.igem.org/Part:BBa_ K1897017</a></td></tr>
+</tbody></table></p></br>
 							<hr>

Difference between revisions of "Team:NUS Singapore/Parts"

Revision as of 04:20, 18 October 2016